Cyxone AB (publ) (CYXO.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 28.21 Million SEK | -33.1% |
| 2022 | 42.17 Million SEK | -5.85% |
| 2021 | 44.79 Million SEK | -8.37% |
| 2020 | 48.88 Million SEK | 39.0% |
| 2019 | 35.16 Million SEK | 127.83% |
| 2018 | 15.43 Million SEK | 74.93% |
| 2017 | 8.82 Million SEK | 569.46% |
| 2016 | 1.31 Million SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.46 Million SEK | -11.61% |
| 2024 Q1 | 5.78 Million SEK | 9.74% |
| 2023 Q2 | 7.58 Million SEK | 27.23% |
| 2023 Q1 | 5.96 Million SEK | 225.07% |
| 2023 FY | 19.23 Million SEK | -54.39% |
| 2023 Q4 | 5.26 Million SEK | 1.58% |
| 2023 Q3 | 5.18 Million SEK | -31.68% |
| 2022 FY | 42.17 Million SEK | -5.85% |
| 2022 Q3 | 11.26 Million SEK | -11.33% |
| 2022 Q4 | 1.83 Million SEK | -83.71% |
| 2022 Q2 | 12.7 Million SEK | -23.84% |
| 2022 Q1 | 16.67 Million SEK | 21.32% |
| 2021 Q1 | 8.61 Million SEK | -27.65% |
| 2021 Q2 | 11.45 Million SEK | 33.05% |
| 2021 Q3 | 10.97 Million SEK | -4.22% |
| 2021 FY | 44.79 Million SEK | -8.37% |
| 2021 Q4 | 13.74 Million SEK | 25.28% |
| 2020 Q4 | 11.9 Million SEK | -5.59% |
| 2020 Q1 | 10.09 Million SEK | -50.52% |
| 2020 FY | 48.88 Million SEK | 39.0% |
| 2020 Q2 | 14.18 Million SEK | 40.53% |
| 2020 Q3 | 12.6 Million SEK | -11.13% |
| 2019 Q4 | 20.4 Million SEK | 258.36% |
| 2019 FY | 35.16 Million SEK | 127.83% |
| 2019 Q3 | 5.69 Million SEK | 31.24% |
| 2019 Q2 | 4.33 Million SEK | -8.9% |
| 2019 Q1 | 4.76 Million SEK | 4.75% |
| 2018 Q1 | 2.7 Million SEK | -16.66% |
| 2018 FY | 15.43 Million SEK | 74.93% |
| 2018 Q2 | 3.81 Million SEK | 40.9% |
| 2018 Q3 | 4.37 Million SEK | 14.8% |
| 2018 Q4 | 4.54 Million SEK | 3.93% |
| 2017 Q1 | 1.49 Million SEK | 164.83% |
| 2017 Q2 | 2.58 Million SEK | 73.04% |
| 2017 FY | 8.82 Million SEK | 569.46% |
| 2017 Q3 | 1.51 Million SEK | -41.36% |
| 2017 Q4 | 3.24 Million SEK | 114.44% |
| 2016 Q4 | 563 Thousand SEK | -54.38% |
| 2016 Q1 | 307 Thousand SEK | 0.0% |
| 2016 FY | 1.31 Million SEK | 0.0% |
| 2016 Q2 | 1.15 Million SEK | 276.87% |
| 2016 Q3 | 1.23 Million SEK | 6.66% |
| 2015 FY | - SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Simris Alg AB (publ) | 38.64 Million SEK | 26.986% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 91.224% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 92.111% |
| Xintela AB (publ) | 57.31 Million SEK | 50.775% |
| Active Biotech AB (publ) | 44.8 Million SEK | 37.035% |
| Amniotics AB (publ) | 29.07 Million SEK | 2.951% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -92.548% |
| BioArctic AB (publ) | 89.62 Million SEK | 68.521% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 98.137% |
| Camurus AB (publ) | 1.05 Billion SEK | 97.337% |
| Cantargia AB (publ) | 290.01 Million SEK | 90.272% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -28.86% |
| CombiGene AB (publ) | 44.14 Million SEK | 36.087% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 80.268% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 0.397% |
| Genovis AB (publ.) | 88.19 Million SEK | 68.01% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 75.482% |
| Mendus AB (publ) | 129.13 Million SEK | 78.152% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -288.195% |
| Intervacc AB (publ) | 79.78 Million SEK | 64.637% |
| Kancera AB (publ) | 63.07 Million SEK | 55.271% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -411.216% |
| LIDDS AB (publ) | 27.75 Million SEK | -1.665% |
| Lipum AB (publ) | 37.3 Million SEK | 24.373% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -288.944% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 79.241% |
| NextCell Pharma AB | -576.01 Thousand SEK | 4998.102% |
| OncoZenge AB (publ) | 15.9 Million SEK | -77.391% |
| Saniona AB (publ) | 1.07 Million SEK | -2519.684% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 84.475% |
| Ziccum AB (publ) | 27.87 Million SEK | -1.205% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -72.026% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 90.812% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 33.82% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -59.554% |
| Corline Biomedical AB | 30.16 Million SEK | 6.477% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 51.381% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 66.076% |
| Aptahem AB (publ) | 10.01 Million SEK | -181.775% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 79.053% |
| Fluicell AB (publ) | 28.61 Million SEK | 1.408% |
| Biovica International AB (publ) | 133.72 Million SEK | 78.901% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -42.567% |
| AcouSort AB (publ) | 25.87 Million SEK | -9.035% |
| Abliva AB (publ) | 27.86 Million SEK | -1.249% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 85.419% |
| 2cureX AB (publ) | 36.51 Million SEK | 22.739% |
| I-Tech AB | 40.14 Million SEK | 29.725% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 96.717% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 74.203% |
| Biosergen AB | 26.8 Million SEK | -5.241% |
| Nanologica AB (publ) | 69.88 Million SEK | 59.629% |
| SynAct Pharma AB | 224.49 Million SEK | 87.432% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 36.133% |
| BioInvent International AB (publ) | 441.4 Million SEK | 93.608% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -17.783% |
| Alzinova AB (publ) | 36.39 Million SEK | 22.48% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 90.263% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -259.127% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 74.562% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -91.932% |